Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in high-risk melanoma patients

Given its ability to induce both humoral and cellular immune responses, NY-ESO-1 has been considered a suitable antigen for a cancer vaccine. Despite promising results from early-phase clinical studies in melanoma patients, NY-ESO-1 vaccine immunotherapy has not been widely investigated in larger tr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Immunol Res
Hlavní autoři: Pavlick, Anna, Blazquez, Ana Belen, Meseck, Marcia, Lattanzi, Michael, Ott, Patrick A., Marron, Thomas U, Holman, Rose Marie, Mandeli, John, Salazar, Andres, McClain, Christopher, Gimenez, Gustavo, Balan, Sreekumar, Gnjatic, Sacha, Sabado, Rachel Lubong, Bhardwaj, Nina
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6946846/
https://ncbi.nlm.nih.gov/pubmed/31699709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-19-0545
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky